Inactivated influenza vaccines for prevention of community-acquired pneumonia: The limits of using nonspecific outcomes in vaccine effectiveness studies

Epidemiology

Volumn 24, Issue 4, 2013, Pages 530-537

  Ferdinands, Jill M ^a,b   Gargiullo, Paul ^a   Haber, Michael ^c   Moore, Matthew ^a   Belongia, Edward A ^d   Shay, David K ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b BATTELLE MEMORIAL INSTITUTE   (United States)

^c EMORY UNIVERSITY   (United States)

^d MARSHFIELD CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; DRUG EFFICACY; HEALTH CARE DELIVERY; HUMAN; INCIDENCE; INFECTION RATE; INFECTION RISK; INFLUENZA; INFLUENZA VACCINATION; PRIORITY JOURNAL; STOCHASTIC MODEL;

COMMUNITY-ACQUIRED INFECTIONS; COMPUTER SIMULATION; HUMANS; INCIDENCE; INFLUENZA VACCINES; MODELS, BIOLOGICAL; MODELS, STATISTICAL; PNEUMONIA; RESEARCH DESIGN; STOCHASTIC PROCESSES; TREATMENT OUTCOME; UNITED STATES; VACCINES, INACTIVATED;

EID: 84879867666     PISSN: 10443983     EISSN: 15315487     Source Type: Journal    
DOI: 10.1097/EDE.0b013e3182953065     Document Type: Article

References (40)

1. Jackson ML, Neuzil KM, Thompson WW, et al. The burden of community- acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis. 2004;39: 1642-1650.
2. Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis. 2008;198: 962-970.
3. Brundage JF. Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness. Lancet Infect Dis. 2006;6: 303-312.
4. Belongia EA, Irving SA, Waring SC, et al. Clinical characteristics and 30-day outcomes for influenza A 2009 (H1N1), 2008-2009 (H1N1), and 2007-2008 (H3N2) infections. JAMA. 2010;304: 1091-1098.
5. Falsey AR, Walsh EE. Viral pneumonia in older adults. Clin Infect Dis. 2006;42: 518-524.
6. Fiore AE, Uyeki TM, Broder K, et al.; Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACI P), 2010. MMWR Recomm Rep. 2010;59(RR-8): 1-62.
7. Mandell LA, Wunderink RG, Anzueto A, et al.; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(suppl 2):S27-S72.
8. L im WS, Baudouin SV, George RC, Hill AT, Jamieson C, et al. British Thoracic Society guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009;64(suppl II):iii1-iii55.
9. Baxter R, Ray GT, Fireman BH. Effect of influenza vaccination on hospitalizations in persons aged 50 years and older. Vaccine. 2010;28: 7267-7272.
10. N ichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med. 2007;357: 1373-1381.
11. N ichol KL, Nordin J, Mullooly J, Lask R, Fillbrandt K, Iwane M. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med. 2003;348: 1322-1332.
12. Hak E, Nordin J, Wei F, et al. Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations. Clin Infect Dis. 2002;35: 370-377.
13. Jefferson T, Rivetti D, Rivetti A, Rudin M, Di Pietrantonj C, Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet. 2005;366: 1165-1174.
14. Jackson LA, Jackson ML, Nelson JC, Neuzil KM, Weiss NS. Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int J Epidemiol. 2006;35: 337-344.
15. Simonsen L, Viboud C, Taylor RJ, Miller MA, Jackson L. Influenza vaccination and mortality benefits: new insights, new opportunities. Vaccine. 2009;27: 6300-6304.
16. Fireman B, Lee J, Lewis N, Bembom O, van der Laan M, Baxter R. Influenza vaccination and mortality: differentiating vaccine effects from bias. Am J Epidemiol. 2009;170: 650-656.
17. Jackson ML, Nelson JC, Weiss NS, Neuzil KM, Barlow W, Jackson LA. Influenza vaccination and risk of community-acquired pneumonia in immunocompetent elderly people: a population-based, nested case-control study. Lancet. 2008;372: 398-405.
18. Belongia EA, Shay DK. Influenza vaccine for community-acquired pneumonia. Lancet. 2008;372: 352-354.
19. Vose D. Quantitative Risk Analysis: A Guide to Monte Carlo Simulation Modeling. New York: Wiley; 1996.
20. Barrett PN, Berezuk G, Fritsch S, et al. Efficacy, safety, and immunogenicity of a Vero-cellculture-derived trivalent influenza vaccine: a multicentre, double- blind, randomised, placebo-controlled trial. Lancet. 2011;377: 751-759.
21. Frey S, Vesikari T, Szymczakiewicz-Multanowska A, et al. Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in healthy adults. Clin Infec Dis. 2010;51: 997-1004.
22. Jackson LA, Gaglani MJ, Keyserling HL, et al. Safety, efficacy and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons. BMC Infectious Diseases. 2010;10:71.
23. Beran J, Vesikari T, Wertzova V, et al. Efficacy of inactivated splitvirus influenza vaccine against culture-confirmed influenza in healthy adults: a prospective, randomized, placebo-controlled trial. J Infect Dis. 2009;200: 1861-1869.
24. Monto AS, Ohmit SE, Petrie JG, et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med. 2009;361: 1260-1267.
25. Ohmit SE, Victor JC, Teich ER, et al. Prevention of symptomatic seasonal influenza in 2005-2006 by inactivated and live attenuated vaccines. J Infect Dis. 2008;198: 312-317.
26. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infec Dis. 2012;12: 36-44.
27. C enters for Disease Control and Prevention. Final state-level influenza vaccination coverage estimates for the 2010-11 season-United States, National Immunization Survey and Behavioral Risk Factor Surveillance System, August 2010 through May 2011. Available at: http://www.cdc.gov/ flu/professionals/ vaccination/vaccinecoverage.htm. Accessed 2 July 2011.
28. DeStefano F, Eaker ED, Broste SK, et al. Epidemiologic research in an integrated regional medical care system: the Marshfield Epidemiologic Study Area. J Clin Epidemiol. 1996;49: 643-652.
29. T ate JE, Curns AT, Cortese MM, et al. Burden of acute gastroenteritis hospitalizations and emergency department visits in US children that is potentially preventable by rotavirus vaccination: a probe study using the now-withdrawn rotashield vaccine. Pediatrics. 2009;123: 744-749.
30. Moore DP, Klugman KP, Madhi SA. Role of Streptococcus pneumoniae in hospitalization for acute community-acquired pneumonia associated with culture-confirmed Mycobacterium tuberculosis in children: a pneumococcal conjugate vaccine probe study. Pediatr Infect Dis J. 2010;29: 1099-1004.
31. von Baum H, Schweiger B, Welte T, et al.; CAPNETZ Study Group. How deadly is seasonal influenza-associated pneumonia? The German Competence Network for Community-Acquired Pneumonia. Eur Respir J. 2011;37: 1151-1157.
32. Johnstone J, Majumdar SR, Fox JD, Marrie TJ. Viral infection in adults hospitalized with community-acquired pneumonia: prevalence, pathogens, and presentation. Chest. 2008;134: 1141-1148.
33. Knol MJ, Vandenbroucke JP, Scott P, Egger M. What do case-control studies estimate? Survey of methods and assumptions in published casecontrol research. Am J Epidemiol. 2008;168: 1073-1081.
34. T essmer A, Welte T, Schmidt-Ott R, et al.; CAPNETZ study group. Influenza vaccination is associated with reduced severity of communityacquired pneumonia. Eur Respir J. 2011;38: 147-153.
35. Spaude KA, Abrutyn E, Kirchner C, Kim A, Daley J, Fisman DN. Influenza vaccination and risk of mortality among adults hospitalized with community-acquired pneumonia. Arch Intern Med. 2007;167: 53-59.
36. Hernán MA, Lipsitch M. Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials. Clin Infect Dis. 2011;53: 277-279.
37. C enters for Disease Control and Prevention. Prevention of pneumococcal disease. MMWR Morb Mortal Wkly Rep. 1997;46(RR-8): 1-20.
38. Bridges CB, Thompson WW, Meltzer MI, et al. Effectiveness and costbenefit of influenza vaccination of healthy working adults: A randomized controlled trial. JAMA. 2000;284: 1655-1663.
39. Uzicanin A, Thompson M, Smith P, et al.; Maine 2009 Influenza A (H1N1) Vaccine Effectiveness Evaluation Group. Effectiveness of 1 dose of influenza A (H1N1) 2009 monovalent vaccines in preventing reversetranscription polymerase chain reaction-confirmed H1N1 infection among school-age children in maine. J Infect Dis. 2012;206: 1059-1068.
40. Mawas F, Ho MM, Corbel MJ. Current progress with Moraxella catarrhalis antigens as vaccine candidates. Expert Rev Vaccines. 2009;8: 77-90.